JAKAFI XR - (EQ 11MG BASE; TABLET,EXTENDED RELEASE)

Generic Name	RUXOLITINIB PHOSPHATE	**Innovator**	None
Dosage	EQ 11MG BASE; TABLET,EXTENDED RELEASE	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	JAKAFI/JAKAFI XR is a kinase inhibitor indicated for treatment of: ? intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults. ? polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea. ? steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. ? chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

JAKAFI XR - (EQ 22MG BASE, EQ 33MG BASE, EQ 44MG BASE, EQ 55MG BASE; TABLET,EXTENDED RELEASE)

Generic Name	RUXOLITINIB PHOSPHATE	**Innovator**	None
Dosage	EQ 22MG BASE, EQ 33MG BASE, EQ 44MG BASE, EQ 55MG BASE; TABLET,EXTENDED RELEASE	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	JAKAFI/JAKAFI XR is a kinase inhibitor indicated for treatment of: ? intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults. ? polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea. ? steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. ? chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.